IGFBP-3 exhibits intrinsic growth-regulating effects that are not yet fully understood, but have evoked interest with regards to a possible role of IGFBP-3 as a prognostic tumor marker. Low IGFBP-3 and IGF-I levels are observed in GH deficiency or GH resistance, also epidemiologic studies suggest that low IGFBP-3 is associated with greater risk of aggressive, metastatic prostate cancers. The elevated serum IGFBP-3 and IGF-I levels indicate a sustained overproduction of GH, or excessive rhGH therapy. Both conditions are associated with generalized organomegaly, hypertension, diabetes, cardiomyopathy, osteoarthritis, and diminished longevity.
The Ansh Labs' Total IGFBP-3 ELISA kit is a quantitative two-step sandwich immunoassay. The Ansh Labs Total IGFBP-3 Assay uses an acidification and neutralization method to dissociate IGFBP-3 from all the binding subunits.
For Research Use Only within the United States. Ansh Labs, located just south of Houston Texas, is an FDA registered manufacturer of diagnostic test kits, antibodies, antigens, and proteins.